Indivior Pharmaceuticals, Inc 6-K, filed Mar 6, 2024
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2024-03-06
For: 2024-03-06
View Original
Added on
July 07, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on March 6, 2024.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: March 06, 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit No.
|
Description of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: March 6,
2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit 99.1
INDIVIOR PLC (THE 'COMPANY')
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR') AND PERSONS
CLOSELY ASSOCIATED WITH THEM
The Company announces that on March 5, 2024, Mark Crossley, Chief
Executive Officer and a PDMR, received 91,204 ordinary shares in
the Company of $0.50 each ('Shares').
This arose as a result of the release of awards granted on March 5,
2019 and August 8, 2019 under the Indivior Long-Term Incentive
Plan, which vested in respect of a total of 159,311 Shares on March
5, 2021 and which were then subject to a two-year post-vesting
holding period. Following the end of the holding period, the
Shares were released on March 5, 2024 on a net settled basis,
resulting in the delivery of 91,204 Shares.
Following this transaction, Mark Crossley has a beneficial interest
in 181,236 Shares in the Company.
This notification is made in accordance with the requirements
of the UK Market Abuse Regulation.
Kathryn Hudson
Company Secretary
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
||
|
a)
|
Name
|
Mark Crossley
|
|
|
2
|
Reason for the notification
|
||
|
a)
|
Position/status
|
Director / PDMR - Chief Executive Officer
|
|
|
b)
|
Initial notification /Amendment
|
Initial notification
|
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
Indivior PLC
|
|
|
b)
|
LEI
|
213800V3NCQTY7IED471
|
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
||
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.50
GB00BN4HT335
|
|
|
b)
|
Nature of the transaction
|
Release of Shares following the end of the two-year holding period
after vesting of an award granted under the Indivior Long-Term
Incentive Plan.
|
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
N/A
|
91,204
|
||
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
|
e)
|
Date of the transaction
|
March 5, 2024
|
|
Indivior PLC's Legal Entity Identifier code is
213800V3NCQTY7IED471.